IARTIntegra LifeSciences Holdings Corporation

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Manufacturing restart and margin gains drive stabilization as company pursues deleveraging.

Integra LifeSciences’ second quarter results reflected ongoing business challenges, as management attributed the quarter’s flat revenue to ongoing reimbursement pressures in certain product lines and challenging year-over-year comparisons, especially in the tissue reconstruction segment. CFO Lea Daniels Knight acknowledged that, “the quarter’s outperformance in adjusted EPS was largely driven by operational execution and favorable tariff dynamics,” but reiterated that the company is operating in

Integra LifeSciences Holdings earnings and guidance draw investor focus Integra LifeSciences Holdings (IART) has come back into focus after reporting second quarter 2026 results with a swing back to profitability, while also updating quarterly and full year revenue guidance on July 29. The company reported second quarter sales of US$418.76 million compared with US$415.61 million a year earlier. Net income was US$4.48 million compared with a net loss of US$484.07 million in the prior year...

Integra LifeSciences Holdings reported past second-quarter 2026 results with sales of US$418.76 million and net income of US$4.48 million, and issued third-quarter revenue guidance of US$410 million to US$425 million while slightly trimming its full-year 2026 outlook to US$1.65 billion to US$1.70 billion due to currency effects. The swing from a very large prior-year net loss to a modest profit, while maintaining overall revenue guidance, points to meaningful operational and earnings quality...

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 million. The company expects next quarter’s revenue to be around $417.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 15.8% above analysts’ consensus estimates.

Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 10.1% in the afternoon session after the company reported a second-quarter earnings beat was overshadowed by concerns about flat revenue growth and declining profitability.

Bassett Furniture, Aveanna Healthcare and Integra LifeSciences are highlighted as potential breakout stocks using support and resistance levels ahead of August.

Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.

Moby summary of Integra LifeSciences Holdings Corporation's Q2 2026 earnings call

Integra LifeSciences (NASDAQ:IART) reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, ex

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Integra (IART) delivered earnings and revenue surprises of +16.67% and -0.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 million. The company expects next quarter’s revenue to be around $417.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 15.8% above analysts’ consensus estimates.

Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.

Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results this Wednesday morning. Here’s what to look for.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.

IART vs. SONVY: Which Stock Is the Better Value Option?

Integra LifeSciences Holdings recently drew attention after a run of earnings beats and favorable analyst assessments coincided with preparations for its second-quarter 2026 results release and conference call, now in the past. The combination of a consistent pattern of topping earnings expectations and upward estimate revisions has reinforced investor confidence in the company’s operational execution. Next, we will examine how this earnings outperformance track record shapes Integra...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Integra LifeSciences Holdings has rebounded sharply in the past year after a difficult few years, and at the current US$19.85 share price both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples still indicate the stock is trading at a discount to what the business may be worth. Over the past 5 years the stock has fallen 70.4%, which means the recent strength comes after a long period of weak returns for longer term holders. The business can support its valuation...

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?